{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:24:15Z","timestamp":1790270655452,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The majority of locally advanced esophageal squamous cell carcinoma (ESCC) patients do not achieve a pathological complete response (NPCR) after neoadjuvant chemoimmunotherapy (NCIT), and their prognosis exhibits significant heterogeneity. This study aimed to establish a pathological subtyping system for NPCR patients to guide precision adjuvant therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 243 patients with locally advanced ESCC who underwent NCIT followed by esophagectomy. NPCR patients were categorized into three pathological subtypes based on the anatomical sites of residual disease: T+N+ (residual tumor in both primary site and lymph nodes), T+N0 (residual tumor confined to primary site only), and T0N+ (residual disease in lymph nodes only). Survival outcomes were compared, and the efficacy of adjuvant immunotherapy was evaluated within each subtype. Prognostic nomograms for disease-free survival (DFS) and overall survival (OS) were constructed and validated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 176 NPCR patients, the novel subtyping system achieved significant prognostic stratification. The T+N+ subtype demonstrated the poorest survival outcomes, while the T0N+ subtype did not significantly differ from the PCR cohort. Notably, adjuvant immunotherapy provided significant survival benefits exclusively in the T+N0 subtype (DFS: HR\u00a0=\u00a03.45, 95% CI: 1.17-10.17, P\u00a0=\u00a00.025; OS: HR\u00a0=\u00a04.17, 95% CI: 1.07-16.23, P\u00a0=\u00a00.039), with no significant benefits observed in either the T+N+ or T0N+ subtypes. Based on these findings, we developed and internally validated prognostic nomograms integrating pathological subtype, ypTNM stage, and other key clinicopathological variables, which demonstrated good predictive accuracy (C-index &amp;gt;0.75) for individualized risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We propose a novel and practical pathological subtyping framework for NPCR ESCC patients that effectively resolves prognostic heterogeneity and identifies, the T+N0 subtype as the primary beneficiary of adjuvant immunotherapy. The developed nomograms provide a user-friendly tool to facilitate personalized postoperative management and adjuvant therapy decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1742272","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:56:55Z","timestamp":1773817015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Residual disease subtyping predicts survival and guides adjuvant immunotherapy in esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Huiya","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, People's Hospital Of Huantai County","place":["Zibo, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyu","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhansheng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Esophageal Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100789","article-title":"How we treat esophageal squamous cell carcinoma","volume":"8","author":"Puhr","year":"2023","journal-title":"ESMO Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-074962","article-title":"Advances in diagnosis and management of cancer of the esophagus","volume":"385","author":"Deboever","year":"2024","journal-title":"Bmj"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.ccell.2024.09.008","article-title":"A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: the Keystone-001 trial","volume":"42","author":"Shang","year":"2024","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1066527","article-title":"Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251316179","article-title":"Adjuvant treatment after neoadjuvant chemoradiotherapy and surgery in patients with esophageal squamous cell carcinoma: a real-world study","volume":"17","author":"Geng","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e008942","DOI":"10.1136\/jitc-2024-008942","article-title":"Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study","volume":"12","author":"Feng","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102579","article-title":"Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial","volume":"71","author":"Wu","year":"2024","journal-title":"Eclinicalmedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611108","article-title":"Neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma with non-regional cervical lymph node metastasis: a retrospective pilot study","volume":"16","author":"Zeng","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003546","article-title":"Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study","volume":"112","author":"Chen","year":"2025","journal-title":"Int J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-11141-4","article-title":"CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma","volume":"35","author":"Shi","year":"2025","journal-title":"Eur Radiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e011149","DOI":"10.1136\/jitc-2024-011149","article-title":"Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy","volume":"13","author":"Zhang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-024-02006-x","article-title":"Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1186\/s12885-025-14785-7","article-title":"Enhanced prognosis prediction model in esophageal cancer via lymph node assessment post-neoadjuvant","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33208","article-title":"Selection of high-risk individuals for esophageal cancer screening: a prediction model of esophageal squamous cell carcinoma based on a multicenter screening cohort in rural China","volume":"148","author":"Chen","year":"2021","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-023-13430-6","article-title":"Learning curve of robot-assisted lymph node dissection of the left recurrent laryngeal nerve: a retrospective study of 417 patients","volume":"30","author":"Duan","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001098","article-title":"International consensus on standardization of data collection for complications associated with esophagectomy: Esophagectomy Complications Consensus Group (ECCG)","volume":"262","author":"Low","year":"2015","journal-title":"Ann Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/dote.12533","article-title":"Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals","volume":"29","author":"Rice","year":"2016","journal-title":"Dis Esophagus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2023.03.008","article-title":"Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma","volume":"186","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","article-title":"Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment","volume":"11","author":"Zheng","year":"2020","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13073-024-01320-9","article-title":"Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma","volume":"16","author":"Ji","year":"2024","journal-title":"Genome Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102334","article-title":"ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1330928","article-title":"Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13014-015-0450-4","article-title":"Residual lymph node status is an independent prognostic factor in esophageal squamous cell carcinoma with pathologic T0 after preoperative radiotherapy","volume":"10","author":"Wang","year":"2015","journal-title":"Radiat Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1742272\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:56:56Z","timestamp":1773817016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1742272\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1742272"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1742272","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1742272"}}